Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)
Data(s) |
04/08/2014
|
---|---|
Resumo |
Current practice in Switzerland for the mobilization of autologous stem cells in patients with myeloma is combining vinorelbine chemotherapy and granulocyte-colony stimulating factor (G-CSF) cytokine stimulation. We prospectively investigated adding intravenous plerixafor to the vinorelbine/G-CSF combination (VGP), and compared it with vinorelbine/plerixafor (VP) and G-CSF/plerixafor (GP) combinations. In a final cohort (VP-late), plerixafor was given on the first day of CD34 + cells increasing to > 15 000/mL peripheral blood. Four consecutive cohorts of 10 patients with myeloma were studied. We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF. VGP was superior in mobilizing peripheral stem and progenitor cells compared to the three double combinations (VP, GP and VP-late), and GP mobilized better than VP. Our data indicate that the triple combination of VGP is an efficient strategy to collect autologous CD34 + cells, with G-CSF contributing predominantly in this concept. Plerixafor can be safely added to G-CSF and/or vinorelbine chemotherapy. |
Formato |
application/pdf |
Identificador |
http://boris.unibe.ch/62871/1/GMB_BM_PAV-trial%20Leukemia%20and%20Lymphoma%202015.pdf Schmid, Andrea; Friess, Dorothea; Mansouri Taleghani, Behrouz; Keller, Peter; Müller, Beatrice Ursula; Baerlocher, Gabriela M.; Leibundgut, Kurt; Pabst, Thomas (2014). Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia & lymphoma, 56(3), pp. 608-614. Informa Healthcare 10.3109/10428194.2014.927454 <http://dx.doi.org/10.3109/10428194.2014.927454> doi:10.7892/boris.62871 info:doi:10.3109/10428194.2014.927454 info:pmid:24884311 urn:issn:1042-8194 |
Idioma(s) |
eng |
Publicador |
Informa Healthcare |
Relação |
http://boris.unibe.ch/62871/ |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
Schmid, Andrea; Friess, Dorothea; Mansouri Taleghani, Behrouz; Keller, Peter; Müller, Beatrice Ursula; Baerlocher, Gabriela M.; Leibundgut, Kurt; Pabst, Thomas (2014). Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia & lymphoma, 56(3), pp. 608-614. Informa Healthcare 10.3109/10428194.2014.927454 <http://dx.doi.org/10.3109/10428194.2014.927454> |
Palavras-Chave | #610 Medicine & health |
Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |